心脑康胶囊联合曲美他嗪治疗冠心病心绞痛的临床研究

目的探讨心脑康胶囊联合曲美他嗪治疗冠心病心绞痛的临床疗效。方法选取2015年7月—2016年7月在天津市武清区中医医院治疗的冠心病心绞痛患者82例,根据治疗方案的差别分为对照组(41例)和治疗组(41例)。对照组口服盐酸曲美他嗪片,1片/次,3次/d。治疗组在对照组的基础上口服心脑康胶囊,4粒/次,3次/d。两组患者均治疗8周。治疗后,观察两组患者的临床疗效,并比较两组的临床症状、血清细胞因子、血液流变学指标的变化。结果治疗后,对照组和治疗组的总有效率分别为82.93%、97.56%,两组比较差异具有统计学意义(P0.05)。两组患者心绞痛发作次数、心绞痛持续时间和硝酸甘油用量均少于同组治疗前(P0.05),且治疗组减少的更显著(P0.05)。两组患者血清CRP、IL-6、s ICAM-1、s VCAM-1、c Tn I和NT-pro BNP水平均显著降低,VEGF和NO水平显著升高(P0.05);且治疗组上述指标改善的更明显(P0.05)。两组WBV、PV和FIB均低于同组治疗前(P0.05),且治疗组降低的更显著,两组比较差异具有统计学意义(P0.05)。结论心脑康胶囊联合曲美他嗪治疗冠心病心绞痛效果显著,可明显改善患者症状及血清学指标,具有一定的临床推广应用价值。

Clinical study of Xinnaokang Capsules combined with trimetazidine in treatment of coronary heart disease with angina pectoris

Objective To investigate the clinical curative effect of Xinnaokang Capsules combined with trimetazidine in treatment of coronary heart disease with angina pectoris. Methods Patients (82 cases) with coronary heart disease with angina pectoris in Wuqing Hospital of Traditional Chinese Medicine in Tianjin from July 2015 to July 2016 were divided into control group (41 cases) and treatment group (41 cases) based on different treatments. Patients in control group were po administered with Trimetazidine Dihydrochloride Tablets, 1 tablet/time, three times daily. Patients in treatment group were po administered with Xinnaokang Capsules on the basis of control group, 4 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and clinical symptoms, serum cytokines, and blood rheology indexes were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.93% and 97.56%, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris, and dosage of nitroglycerin were lower than those before treatment (P<0.05). And those indexes in the treatment group were decreased more significantly than those in the control group (P<0.05). CRP, IL-6, sICAM-1, sVCAM-1, cTnI, and NT-proBNP in two groups were decreased significantly, but VEGF and NO increased significantly (P<0.05). And those indexes in the treatment group were improved more significantly than those in the control group (P<0.05). WBV, PV, and FIB in two groups were lower than those in the control group (P<0.05). And those indexes in the treatment group were decreased more significantly than those in the control group, and there were differences between two groups (P<0.05). Conclusion Xinnaokang Capsules combined with trimetazidine has a significant clinical effect in treatment of coronary heart disease with angina pectoris, and can significantly improve the symptoms and blood rheology indexes, which has a certain clinical application value.